• Chronic obstructive pulmonary disease (COPD) is highly prevalent in the five largest European markets (France, Germany, Italy, Spain, and the United Kingdom), and a significant proportion of the patient population
requires lifelong treatment.
• Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA)/inhaled corticosteroid (ICS) fixed-dose combination (FDC) triple therapies are poised to penetrate the EU5 COPD markets, where they will
compete with multiple inhaled brands and increasing generic LABA/ICS FDC and LAMA options.
• As payers across the cost-constrained EU5 strive to draw out value for money, this research explored the market access landscape that emerging LABA/LAMA/ICS FDCs will face.

Authors: Kristine Mackin, Ph.D.; Colleen Albacker, Ph.D.; Laura Vinuesa D.V.M. M.Sc.; Janie Cox, Ph.D.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now